Oestrogen-17-sulphamates as inhibitors of steroid sulphatase

Details Oestrogen-17-sulphamates as inhibitors of steroid sulphatase Oestrogen-17-sulphamates as inhibitors of steroid sulphatase

2006-03-03

2011-10-04

Qazi, Sabiha (Department: 1628)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Cyclopentanohydrophenanthrene ring system doai

C514S178000, C514S180000, C514S182000, C552S623000, C552S626000, C552S627000, C552S635000

Reexamination Certificate

active

08030296

ABSTRACT:
There is provided a compound of Formula Iwherein X is a ring system; R1is any one of a sulphamate group, a phosphonate group, a thiophosphonate group, a sulphonate group or a sulphonamide group; R2is any one of a sulphamate group, a phosphonate group, a thiophosphonate group, a sulphonate group or a sulphonamide group; wherein when X is a steroidal structure and both of R1and R2are sulphamate groups, the steroidal ring system (X) represents an oestrogen; and wherein said compound is capable of inhibiting steroid sulphatase (STS) activity and/or is capable of acting as a modulator of cell cycling and/or as a modulator of apoptosis and/or as a modulator of cell growth. There is also provided a compound of Formula VIIIwherein R2is any one of a sulphamate group, a phosphonate group, a thiophosphonate group, a sulphonate group or a sulphonamide group; and wherein said compound is capable of inhibiting steroid sulphatase (STS) activity and/or is capable of acting as a modulator of cell cycling and/or as a modulator of apoptosis and/or as a modulator of cell growth.

REFERENCES:
patent: 3951958 (1976-04-01), Prezewowsky et al.
patent: 3951959 (1976-04-01), Prezewowsky et al.
patent: 6011024 (2000-01-01), Reed et al.
patent: 6017904 (2000-01-01), Reed et al.
patent: 6080735 (2000-06-01), Schwarz et al.
patent: 6087347 (2000-07-01), Koizumi et al.
patent: 6159960 (2000-12-01), Reed et al.
patent: 6339097 (2002-01-01), Festal et al.
patent: 6593321 (2003-07-01), Rao et al.
patent: 6677325 (2004-01-01), Reed et al.
patent: 7067503 (2006-06-01), Potter et al.
patent: 7119081 (2006-10-01), Potter et al.
patent: 7211246 (2007-05-01), Packham et al.
patent: 2003/0100544 (2003-05-01), Scherlitz-Hofmann et al.
patent: B-29741/95 (1995-07-01), None
patent: 100 06 155 (2000-12-01), None
patent: 1 479 362 (1977-07-01), None
patent: 1 479 934 (1977-07-01), None
patent: 1 482 285 (1977-08-01), None
patent: 50-32160 (1975-03-01), None
patent: 50-32161 (1975-03-01), None
patent: WO 93 05064 (1993-03-01), None
patent: WO 96 05216 (1996-02-01), None
patent: WO 96/05216 (1996-02-01), None
patent: WO 98 42729 (1998-10-01), None
patent: WO 99 64013 (1999-12-01), None
patent: WO 00 63228 (2000-10-01), None
patent: WO 01 44268 (2001-06-01), None
patent: WO 01 51055 (2001-07-01), None
patent: WO 01 77139 (2001-10-01), None
Draetta et al “Section V. Topics in Biology”, Annual Reports in Medicinal Chemistry, 31, 1996, Academic Press, San Diego, pp. 241-248.
Theodora VoskogLou-Nomokos et al. (Clinical Research, vol. 9, pp. 4227-4239, Sep. 15, 2003.
Romer, Johannes et al: “Preparation and characterization of the sulfamates of estra-3, 17.xi,-diols. Rapis conversion of 16.alpha.-fluoroestradiol into 16.alpha-fluorestradiol-3, 17.beta.-disul famate”. J. Prakt. Chem. (1999), 341, vol. (6).
Nedvidkova, J et al: “Estrogenic effect of estradiol-sulfamate on the male rat anterior pituitary” XP002182696 J. Steroid Biochem. Mol Biol. (1998), 67(4), pp. 359-362.
Kasch, H. et al: “in vitro selection of sulfatasc inhibitors for tumor diagnosis with PET and for tumor therapy” XP002182697 Forschungszent. Rossendorf (1999), FZR-286, 54-57.
Woo L W L et al: 'Oestrone 3-0-(N-acetyl) stilphamate, a potential molecular proble of the active site of oestrone sulphatase Bioorganic & Medicinal Chemistry Letters, vol. 7, No. 24, (1997), pp. 3075-3080.
Brunner H et al: “Synthese and Antitumoraktivitat von cis-Dichloroplatin (II)-Komplexen mit Ostradiolderivaten” Monatshefte Fur Chemie, Springer Verlag. Wien, AT, vol. 124, No. I, (1993), pp. 83-102.
Lokind et al: “Oral bioavailability of 17.beta-estradiol and prodrugs tested in rats, pigs and dogs” Int J Pharm (1996), 127(2), 155-64.
MacCarthy-Morrogh, L et al: Differential effects of estrone and estrone-3-o-sulfamate derivates on mitotic. Arrest, apoptosis, and microtubule assembly in human breast cancer cells, Cancer Res 2000, Oct 1; 60(19),:5441-50.
Peter Nussbaumer et al: “4,4′-Benzophenone-O, O′-disulfamate: A Potent Inhibitor of Steroid Sulfatase”, Bioorganic & Medicinal Chemistry Letters 12 (2002) 2093-2095.
M J Reed et al: The development of steroid sulphatase inhibitors Endocrine-Related Cancer (1996)3, 9-23.
J. Romer et al: Sulfamates of 3-Hydroxy-estra-1-3-5(10)-triene Derivatives, 182-187.
J. Romer et al:13C NMR Spectroscopic Characterization of Some Sulfamates of 3-Hydroxy-estra-1,3,5(10)-triene Derivatives, 188-191.
Sigfrid Schwarz et: Synthesis of estrogen sulfamates: Compounds with a novel endocrinological profile, Steroids, 1996, vol. 61, December, p. 711.
Jung, H., et al., “Embellistatin, a Microtubule Polymerization Inhibitor, Inhibits Angiogenesis Both in Vitro and Vivo”, Biochemical and Biophysical Research Communications 353 (2007) 376-380, Received Dec. 2, 2006.
Huang, Y., et al., “CIL-102 Interacts with Microtubule Polymerization and Causes Mitotic Arrest following Apoptosis in the Human Prostate Cancer PC-3 Cell Line”, The Journal of Biological Chemistry, vol. 280, No. 4, pp. 2771-2779, issue dated Jan. 28, 2005.
Zhang, H., et al., “Discovery and Structure-Activity Relationship of N-Phenyl-1H-Pyrazolo [3,4-b] Quinolin-4-Amines as a new Series of Potent Apoptosis Inducers”, Bioorganic & Medicinal Chemistry 16, pp. 222-231, (2008 ).
Romer et al., Institute of Bioinorganic and Radiopharmaceutical Chemistry Annual Report,C NMR Spectroscopic Characterization of some Sulfamates of 3-Hydroxy-estra-1,3,5(10)-triene Derivatives, pp. 188-191 (1996).
Romer et al., Institute of Bioinorganic and Radiopharmaceutical Chemistry Annual Report, Sulfamates of 3-Hydroxy-estra-1-3-5(10)-triene Derivatives, pp. 182-187 (1996).

Affiliated with

Also associated with

Rating

Oestrogen-17-sulphamates as inhibitors of steroid sulphatase does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Oestrogen-17-sulphamates as inhibitors of steroid sulphatase, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oestrogen-17-sulphamates as inhibitors of steroid sulphatase will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4266874